SAQA All qualifications and part qualifications registered on the National Qualifications Framework are public property. Thus the only payment that can be made for them is for service and reproduction. It is illegal to sell this material for profit. If the material is reproduced or quoted, the South African Qualifications Authority (SAQA) should be acknowledged as the source.
SOUTH AFRICAN QUALIFICATIONS AUTHORITY 
REGISTERED UNIT STANDARD THAT HAS PASSED THE END DATE: 

Apply the principles of pharmacoeconomics to clinical study outcomes 
SAQA US ID UNIT STANDARD TITLE
259360  Apply the principles of pharmacoeconomics to clinical study outcomes 
ORIGINATOR
SGB Pharmacy 
PRIMARY OR DELEGATED QUALITY ASSURANCE FUNCTIONARY
-  
FIELD SUBFIELD
Field 09 - Health Sciences and Social Services Curative Health 
ABET BAND UNIT STANDARD TYPE PRE-2009 NQF LEVEL NQF LEVEL CREDITS
Undefined  Regular  Level 5  Level TBA: Pre-2009 was L5 
REGISTRATION STATUS REGISTRATION START DATE REGISTRATION END DATE SAQA DECISION NUMBER
Passed the End Date -
Status was "Reregistered" 
2018-07-01  2023-06-30  SAQA 06120/18 
LAST DATE FOR ENROLMENT LAST DATE FOR ACHIEVEMENT
2024-06-30   2027-06-30  

In all of the tables in this document, both the pre-2009 NQF Level and the NQF Level is shown. In the text (purpose statements, qualification rules, etc), any references to NQF Levels are to the pre-2009 levels unless specifically stated otherwise.  

This unit standard does not replace any other unit standard and is not replaced by any other unit standard. 

PURPOSE OF THE UNIT STANDARD 
This unit standard is aimed at individuals entering the pharmaceutical sales field and is applicable across all the subfields within the field of Health Sciences and Social Services. 'Pharmaceutical' includes medicines, medical products, medical devices, scheduled substances, veterinary medicines, products and devices, in accordance with the relevant current legislation. Individuals credited with this standard will be able to apply pharmacoeconomics to demonstrate the cost effectiveness of a product.

The learner will be able to:
  • Explain the theory of pharmacoeconomic analysis.
  • Apply an appropriate method of pharmacoeconomic analysis for specific clinical trial results.
  • Differentiate between the cost-effectiveness of medicines and the cost-effectiveness of specific treatment modalities. 

  • LEARNING ASSUMED TO BE IN PLACE AND RECOGNITION OF PRIOR LEARNING 
  • Mathematical Skills at NQF Level 4.
  • Communication Skills at NQF Level 4.
  • ID 259361: Utilize applicable clinical research findings of pharmaceutical products to achieve a competitive advantage.

    Recognition of Prior Learning:

    A learner may be accredited against this unit standard in terms of recognition of prior learning, based on accreditable evidence of competence in all the required specific outcomes of this, and all the unit standards specified under the heading Learning Assumed to be in Place; and in accordance with the requirements of the relevant ETQA or ETQA that has a Memorandum of Understanding in place with the relevant ETQA. 

  • UNIT STANDARD RANGE 
    N/A 

    Specific Outcomes and Assessment Criteria: 

    SPECIFIC OUTCOME 1 
    Describe the theory of pharmacoeconomic analysis. 

    ASSESSMENT CRITERIA
     

    ASSESSMENT CRITERION 1 
    Pharmacoeconomic terms are listed and defined. 

    ASSESSMENT CRITERION 2 
    Concepts and principles of pharmacoeconomics are discussed to ensure an understanding of the various methods used. 
    ASSESSMENT CRITERION RANGE 
    The principles of pharmacoeconomics include but are not limited to cost-effectiveness, pharmaceutical products, characteristics and stakeholders.
     

    ASSESSMENT CRITERION 3 
    Methods of pharmacoeconomic analysis are described to enable the identification of an appropriate method for a specific study. 

    SPECIFIC OUTCOME 2 
    Apply the appropriate method of pharmacoeconomic analysis for specific clinical study reports. 

    ASSESSMENT CRITERIA
     

    ASSESSMENT CRITERION 1 
    A suitable method of pharmacoeceonomic analysis is identified for specific clinical study results. 

    ASSESSMENT CRITERION 2 
    The identified method of pharmacoeconomic analysis is applied to the specific clinical study results to demonstrate cost effectiveness of the pharmaceutical product. 

    SPECIFIC OUTCOME 3 
    Differentiate between the cost-effectiveness of medicines and the cost-effectiveness of specific treatment modalities. 

    ASSESSMENT CRITERIA
     

    ASSESSMENT CRITERION 1 
    The differences between the cost-effectiveness of various medicines are explained to support a recommendation for the use of a product. 

    ASSESSMENT CRITERION 2 
    The differences between the cost-effectiveness of specific treatment modalities are explained to support a recommendation for use. 


    UNIT STANDARD ACCREDITATION AND MODERATION OPTIONS 
  • Anyone assessing a learner against this unit standard must be registered as an assessor with the relevant ETQA or ETQA that has a Memorandum of Understanding in place with the relevant ETQA.
  • Moderators must be accredited and allocated by the relevant ETQA or ETQA that has a Memorandum of Understanding in place with the relevant ETQA. 

  • UNIT STANDARD ESSENTIAL EMBEDDED KNOWLEDGE 
    N/A 

    UNIT STANDARD DEVELOPMENTAL OUTCOME 
    N/A 

    UNIT STANDARD LINKAGES 
    N/A 


    Critical Cross-field Outcomes (CCFO): 

    UNIT STANDARD CCFO IDENTIFYING 
    Solving problems and making decisions using critical and creative thinking are demonstrated in the application of the appropriate methods of pharmacoeconomic analysis for specific clinical study results. 

    UNIT STANDARD CCFO ORGANISING 
    Organising and managing themselves and their activities responsibly and effectively are demonstrated when differentiating between the cost-effectiveness of medicines and the cost-effectiveness of specific treatment modalities. 

    UNIT STANDARD CCFO COLLECTING 
    Collecting, analysing, organising and evaluating information are demonstrated when differentiating between the cost-effectiveness of medicines and the cost-effectiveness of specific treatment modalities. 

    UNIT STANDARD ASSESSOR CRITERIA 
    N/A 

    REREGISTRATION HISTORY 
    As per the SAQA Board decision/s at that time, this unit standard was Reregistered in 2012; 2015. 

    UNIT STANDARD NOTES 
    Integrated Assessment:

    Assessment will be based on techniques such as:
  • Written assessment.
  • Portfolio of evidence demonstrating understanding.
  • Simulated scenarios.
  • Peer assessment.

    The learner should demonstrate the ability to explain concepts in a clear and understandable manner and in language that is appropriate for the target audience, most often medical doctors.

    Credit Justification:
  • Classroom Learning, 16 hours, 1.6 credits
  • Self Study, 16 hours, 1.6 credits
  • Resource centre utilisation, 8 hours, 0.8 credits 

  • QUALIFICATIONS UTILISING THIS UNIT STANDARD: 
      ID QUALIFICATION TITLE PRE-2009 NQF LEVEL NQF LEVEL STATUS END DATE PRIMARY OR DELEGATED QA FUNCTIONARY
    Elective  63969   National Certificate: Pharmaceutical Sales Representation  Level 5  Level TBA: Pre-2009 was L5  Passed the End Date -
    Status was "Reregistered" 
    2023-06-30  CHIETA 


    PROVIDERS CURRENTLY ACCREDITED TO OFFER THIS UNIT STANDARD: 
    This information shows the current accreditations (i.e. those not past their accreditation end dates), and is the most complete record available to SAQA as of today. Some Primary or Delegated Quality Assurance Functionaries have a lag in their recording systems for provider accreditation, in turn leading to a lag in notifying SAQA of all the providers that they have accredited to offer qualifications and unit standards, as well as any extensions to accreditation end dates. The relevant Primary or Delegated Quality Assurance Functionary should be notified if a record appears to be missing from here.
     
    NONE 



    All qualifications and part qualifications registered on the National Qualifications Framework are public property. Thus the only payment that can be made for them is for service and reproduction. It is illegal to sell this material for profit. If the material is reproduced or quoted, the South African Qualifications Authority (SAQA) should be acknowledged as the source.